{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:32:09Z","timestamp":1791037929060,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11912-022-01192-5","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:02:36Z","timestamp":1646118156000},"page":"671-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neutropenia and Infection Prophylaxis in Childhood Cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Stephanie","family":"Villeneuve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Aftandilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"14","key":"1192_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30(14):1663\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.8018.","journal-title":"J Clin Oncol"},{"issue":"Pt B","key":"1192_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101733","volume":"71","author":"F Erdmann","year":"2021","unstructured":"Erdmann F, Frederiksen LE, Bonaventure A, et al. Childhood cancer: Survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 2021;71(Pt B): 101733. https:\/\/doi.org\/10.1016\/j.canep.2020.101733.","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","volume":"124","author":"D O'Connor","year":"2014","unstructured":"O\u2019Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124(7):1056\u201361. https:\/\/doi.org\/10.1182\/blood-2014-03-560847.","journal-title":"Blood"},{"issue":"6","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/ejh.13162","volume":"101","author":"C Calitri","year":"2018","unstructured":"Calitri C, Ruberto E, Castagnola E. Antibiotic prophylaxis in neutropenic children with acute leukemia: Do the presently available data really support this practice? Eur J Haematol. 2018;101(6):721\u20137. https:\/\/doi.org\/10.1111\/ejh.13162.","journal-title":"Eur J Haematol"},{"issue":"7","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1592\/phco.31.7.642","volume":"31","author":"RN King","year":"2011","unstructured":"King RN, Lager SL. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy. 2011;31(7):642\u20138. https:\/\/doi.org\/10.1592\/phco.31.7.642.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/antibiotics10020152","volume":"10","author":"G Boss\u00f9","year":"2021","unstructured":"Boss\u00f9 G, Di Sario R, Argentiero A, Esposito S. Antimicrobial Prophylaxis and Modifications of the Gut Microbiota in Children with Cancer. Antibiotics. 2021;10(2):152. https:\/\/doi.org\/10.3390\/antibiotics10020152.","journal-title":"Antibiotics"},{"issue":"18","key":"1192_CR7","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1002\/cam4.3249","volume":"9","author":"SE Karol","year":"2020","unstructured":"Karol SE, Sun Y, Tang L, et al. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Med. 2020;9(18):6550\u20135. https:\/\/doi.org\/10.1002\/cam4.3249.","journal-title":"Cancer Med"},{"issue":"11","key":"1192_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/662376","volume":"32","author":"M Kelly","year":"2011","unstructured":"Kelly M, Conway M, Wirth K, Potter-Bynoe G, Billett AL, Sandora TJ. Moving CLABSI prevention beyond the intensive care unit: risk factors in pediatric oncology patients. Infect Control Hosp Epidemiol. 2011;32(11):1079\u201385. https:\/\/doi.org\/10.1086\/662376.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"1192_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/mdr.2019.0393","volume":"27","author":"O Zajac-Spychala","year":"2021","unstructured":"Zajac-Spychala O, Wachowiak J, Gryniewicz-Kwiatkowska O, et al. Prevalence, Epidemiology, Etiology, and Sensitivity of Invasive Bacterial Infections in Pediatric Patients Undergoing Oncological Treatment: A Multicenter Nationwide Study. Microb Drug Resist. 2021;27(1):53\u201363. https:\/\/doi.org\/10.1089\/mdr.2019.0393.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"1192_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pbc.23416","volume":"59","author":"S Alexander","year":"2012","unstructured":"Alexander S, Nieder M, Zerr DM, Fisher BT, Dvorak CC, Sung L. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn? Pediatr Blood Cancer. 2012;59(1):16\u201320. https:\/\/doi.org\/10.1002\/pbc.23416.","journal-title":"Pediatr Blood Cancer"},{"key":"1192_CR11","doi-asserted-by":"publisher","first-page":"CD004386","DOI":"10.1002\/14651858.CD004386.pub3","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386. https:\/\/doi.org\/10.1002\/14651858.CD004386.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1192_CR12","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/cid\/cix644","volume":"65","author":"J Wolf","year":"2017","unstructured":"Wolf J, Tang L, Flynn PM, et al. Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. Clin Infect Dis. 2017;65(11):1790\u20138. https:\/\/doi.org\/10.1093\/cid\/cix644.","journal-title":"Clin Infect Dis"},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JBM.S33906","volume":"4","author":"PH Widjajanto","year":"2013","unstructured":"Widjajanto PH, Sumadiono S, Cloos J, Purwanto I, Sutaryo S, Veerman AJ. Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia. J Blood Med. 2013;4:1\u20139. https:\/\/doi.org\/10.2147\/JBM.S33906.","journal-title":"J Blood Med"},{"issue":"3","key":"1192_CR14","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1097\/INF.0b013e3182793610","volume":"32","author":"K Laoprasopwattana","year":"2013","unstructured":"Laoprasopwattana K, Khwanna T, Suwankeeree P, Sujjanunt T, Tunyapanit W, Chelae S. Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. Pediatr Infect Dis J. 2013;32(3):e94\u20138. https:\/\/doi.org\/10.1097\/INF.0b013e3182793610.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"1192_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2018.12512","volume":"320","author":"S Alexander","year":"2018","unstructured":"\u2022Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2018;320(10):995\u20131004. https:\/\/doi.org\/10.1001\/jama.2018.12512. This randomized controlled trial of pediatric patients with AML or relapsed ALL found that levofloxacin prophylaxis was associated with decreased risk of bacteremia, decrease febrile neutropenia, and decreased exposure to broad spectrum antibiotics without increased risk of invasive fungal disease or c. diff infection.","journal-title":"JAMA"},{"issue":"10","key":"1192_CR16","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1002\/cam4.2395","volume":"8","author":"G Egan","year":"2019","unstructured":"Egan G, Robinson PD, Martinez JPD, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. Cancer Med. 2019;8(10):4536\u201346. https:\/\/doi.org\/10.1002\/cam4.2395.","journal-title":"Cancer Med"},{"issue":"1","key":"1192_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/cid\/ciz1082","volume":"71","author":"T Lehrnbecher","year":"2020","unstructured":"\u2022\u2022Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2020;71(1):226\u201336. https:\/\/doi.org\/10.1093\/cid\/ciz1082. This systematic review provides clinical practice guidelines and a review of key clinical trial results for antibacterial prophylaxis in pediatric oncology patients.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1192_CR18","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","volume":"22","author":"T Lehrnbecher","year":"2021","unstructured":"Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e270\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30725-7.","journal-title":"Lancet Oncol."},{"issue":"4","key":"1192_CR19","doi-asserted-by":"publisher","first-page":"e27564","DOI":"10.1002\/pbc.27564","volume":"66","author":"AW Bartlett","year":"2019","unstructured":"Bartlett AW, Cann MP, Yeoh DK, et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. Pediatr Blood Cancer. 2019;66(4):e27564. https:\/\/doi.org\/10.1002\/pbc.27564.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jpids\/pix030","volume":"7","author":"BT Fisher","year":"2018","unstructured":"Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. J Pediatr Infect Dis Soc. 2018;7(3):191\u20138. https:\/\/doi.org\/10.1093\/jpids\/pix030.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"6","key":"1192_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1192_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/pbc.23005","volume":"56","author":"M Mor","year":"2011","unstructured":"Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011;56(7):1092\u20137. https:\/\/doi.org\/10.1002\/pbc.23005.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1192_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/cid\/cit781","volume":"58","author":"BT Fisher","year":"2014","unstructured":"Fisher BT, Kavcic M, Li Y, et al. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clin Infect Dis. 2014;58(4):502\u20138. https:\/\/doi.org\/10.1093\/cid\/cit781.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"1192_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","volume":"322","author":"BT Fisher","year":"2019","unstructured":"\u2022Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA. 2019;322(17):1673\u201381. https:\/\/doi.org\/10.1001\/jama.2019.15702. This randomized controlled trial of pediatric patients with AML found that caspofungin prophylaxis was associated with a decreased risk of invasive fungal disease compared with fluconazole prophylaxis.","journal-title":"JAMA."},{"issue":"27","key":"1192_CR25","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.20.00158","volume":"38","author":"T Lehrnbecher","year":"2020","unstructured":"\u2022\u2022Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol. 2020;38(27):3205\u201316. https:\/\/doi.org\/10.1200\/JCO.20.00158. This systematic review provides clinical practice guidelines and a review of key clinical trial results for antifungal prophylaxis in pediatric oncology patients.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","volume":"22","author":"AH Groll","year":"2021","unstructured":"Groll AH, Pana D, Lanternier F, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e254\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(20)30723-3.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1192_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM197712292972602","volume":"297","author":"WT Hughes","year":"1977","unstructured":"Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297(26):1419\u201326. https:\/\/doi.org\/10.1056\/NEJM197712292972602.","journal-title":"N Engl J Med"},{"key":"1192_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.09.013","volume":"140","author":"AV Geerlinks","year":"2020","unstructured":"Geerlinks AV, Campigotto A, Science M, Gupta S. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study. Eur J Cancer. 2020;140:71\u20135. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.013.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/pbc.21202","volume":"50","author":"P Prasad","year":"2008","unstructured":"Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer. 2008;50(4):896\u20138. https:\/\/doi.org\/10.1002\/pbc.21202.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MPH.0000000000000771","volume":"39","author":"R Proudfoot","year":"2017","unstructured":"Proudfoot R, Phillips B, Wilne S. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors. J Pediatr Hematol Oncol. 2017;39(3):194\u2013202. https:\/\/doi.org\/10.1097\/MPH.0000000000000771.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"1192_CR31","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/tid.12876","volume":"20","author":"WA Werbel","year":"2018","unstructured":"Werbel WA, Ison MG, Angarone MP, Yang A, Stosor V. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis. 2018;20(3):e12876. https:\/\/doi.org\/10.1111\/tid.12876.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"1192_CR32","doi-asserted-by":"publisher","first-page":"e26752","DOI":"10.1002\/pbc.26752","volume":"65","author":"SB Dixon","year":"2018","unstructured":"Dixon SB, Lane A, O\u2019Brien MM, et al. Viral surveillance using PCR during treatment of AML and ALL. Pediatr Blood Cancer. 2018;65(1):e26752. https:\/\/doi.org\/10.1002\/pbc.26752.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"1192_CR33","doi-asserted-by":"publisher","first-page":"e28673","DOI":"10.1002\/pbc.28673","volume":"67","author":"C Buus-Gehrig","year":"2020","unstructured":"Buus-Gehrig C, Bochennek K, Hennies MT, Klingebiel T, Groll AH, Lehrnbecher T. Systemic viral infection in children receiving chemotherapy for acute leukemia. Pediatr Blood Cancer. 2020;67(12):e28673. https:\/\/doi.org\/10.1002\/pbc.28673.","journal-title":"Pediatr Blood Cancer"},{"key":"1192_CR34","doi-asserted-by":"crossref","unstructured":"Beverley M LP, Kaplan J, Turner N. Flu fighters: Flu vaccine administrations in pediatric hematology oncology patients. J Clin Oncol 2018;36(30).\u00a0https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2018.36.30_suppl.131.","DOI":"10.1200\/JCO.2018.36.30_suppl.131"},{"key":"1192_CR35","doi-asserted-by":"publisher","unstructured":"Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2013;(8):CD006484. https:\/\/doi.org\/10.1002\/14651858.CD006484.pub3.","DOI":"10.1002\/14651858.CD006484.pub3"},{"issue":"5","key":"1192_CR36","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1097\/MPH.0b013e3181d869f3","volume":"32","author":"A Reilly","year":"2010","unstructured":"Reilly A, Kersun LS, McDonald K, Weinberg A, Jawad AF, Sullivan KE. The efficacy of influenza vaccination in a pediatric oncology population. J Pediatr Hematol Oncol. 2010;32(5):e177\u201381. https:\/\/doi.org\/10.1097\/MPH.0b013e3181d869f3.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"27","key":"1192_CR37","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2016.04.053","volume":"34","author":"H Hakim","year":"2016","unstructured":"Hakim H, Allison KJ, Van de Velde LA, et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016;34(27):3141\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.053.","journal-title":"Vaccine"},{"issue":"2","key":"1192_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cam4.596","volume":"5","author":"RS Kotecha","year":"2016","unstructured":"Kotecha RS, Wadia UD, Jacoby P, et al. Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med. 2016;5(2):285\u201393. https:\/\/doi.org\/10.1002\/cam4.596.","journal-title":"Cancer Med"},{"key":"1192_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jpeds.2017.08.071","volume":"191","author":"A Sykes","year":"2017","unstructured":"Sykes A, Gerhardt E, Tang L, Adderson EE. The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia. J Pediatr. 2017;191:218-224 e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.08.071.","journal-title":"J Pediatr"},{"issue":"3","key":"1192_CR40","doi-asserted-by":"publisher","first-page":"e28843","DOI":"10.1002\/pbc.28843","volume":"68","author":"PP Madhusoodhan","year":"2021","unstructured":"Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer. 2021;68(3):e28843. https:\/\/doi.org\/10.1002\/pbc.28843.","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"1192_CR41","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881\u201392. https:\/\/doi.org\/10.1182\/blood.2020008824.","journal-title":"Blood"},{"key":"1192_CR42","unstructured":"UAB. The Pediatric COVID-19 Cancer Case Report. https:\/\/www.uab.edu\/medicine\/icos\/icos-research\/the-pocc-report. Accessed Aug 2021."},{"key":"1192_CR43","unstructured":"Global SJ. Global Registry of COVID-19 in Pediatric Cancer. https:\/\/global.stjude.org\/en-us\/global-covid-19-observatoryand-resource-center-for-childhood-cancer\/registry.html.\u00a0Accessed Aug 2021."},{"issue":"34","key":"1192_CR44","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1200\/JCO.21.00702","volume":"39","author":"EE Johnston","year":"2021","unstructured":"Johnston EE, Martinez I, Davis ES, Caudill C, Richman J, Brackett J, et al. SARS-CoV-2 in childhood cancer in 2020: a disease of disparities. J Clin Oncol. 2021;39(34):3778\u201388. https:\/\/doi.org\/10.1200\/JCO.21.00702.","journal-title":"J Clin Oncol."},{"issue":"7","key":"1192_CR45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJMc2108861","volume":"385","author":"N Kamar","year":"2021","unstructured":"Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021;385(7):661\u20132. https:\/\/doi.org\/10.1056\/NEJMc2108861.","journal-title":"N Engl J Med"},{"issue":"10","key":"1192_CR46","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/pbc.25101","volume":"61","author":"J Wolf","year":"2014","unstructured":"Wolf J, Allison KJ, Tang L, Sun Y, Hayden RT, Flynn PM. No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature. Pediatr Blood Cancer. 2014;61(10):1811\u20135. https:\/\/doi.org\/10.1002\/pbc.25101.","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"1192_CR47","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.ejca.2015.06.126","volume":"51","author":"RA Schoot","year":"2015","unstructured":"Schoot RA, van Ommen CH, Stijnen T, et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial. Eur J Cancer. 2015;51(14):2031\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2015.06.126.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1192_CR48","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S1473-3099(18)30224-X","volume":"18","author":"J Wolf","year":"2018","unstructured":"Wolf J, Connell TG, Allison KJ, et al. Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2018;18(8):854\u201363. https:\/\/doi.org\/10.1016\/S1473-3099(18)30224-X.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1192_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/MMBR.00013-14","volume":"78","author":"D Lebeaux","year":"2014","unstructured":"Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510\u201343. https:\/\/doi.org\/10.1128\/MMBR.00013-14.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"12","key":"1192_CR50","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1473-3099(18)30678-9","volume":"18","author":"J Wolf","year":"2018","unstructured":"Wolf J, Connell TG, Curtis N, Flynn PM. Ethanol lock therapy. Lancet Infect Dis. 2018;18(12):1306. https:\/\/doi.org\/10.1016\/S1473-3099(18)30678-9.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1192_CR51","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1473-3099(18)30267-6","volume":"18","author":"CM Rickard","year":"2018","unstructured":"Rickard CM, Ullman AJ. Bloodstream infection and occlusion of central venous catheters in children. Lancet Infect Dis. 2018;18(8):815\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(18)30267-6.","journal-title":"Lancet Infect Dis"},{"key":"1192_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcrc.2015.11.011","volume":"32","author":"HY Kim","year":"2016","unstructured":"Kim HY, Lee WK, Na S, Roh YH, Shin CS, Kim J. The effects of chlorhexidine gluconate bathing on health care-associated infection in intensive care units: A meta-analysis. J Crit Care. 2016;32:126\u201337. https:\/\/doi.org\/10.1016\/j.jcrc.2015.11.011.","journal-title":"J Crit Care"},{"issue":"5","key":"1192_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/08880018.2015.1013588","volume":"32","author":"CM Raulji","year":"2015","unstructured":"Raulji CM, Clay K, Velasco C, Yu LC. Daily Bathing with Chlorhexidine and Its Effects on Nosocomial Infection Rates in Pediatric Oncology Patients. Pediatr Hematol Oncol. 2015;32(5):315\u201321. https:\/\/doi.org\/10.3109\/08880018.2015.1013588.","journal-title":"Pediatr Hematol Oncol"},{"issue":"15","key":"1192_CR54","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1002\/cncr.33570","volume":"127","author":"DM Zerr","year":"2021","unstructured":"Zerr DM, Milstone AM, Adler AL, Dvorak CC, Fisher BT, Sung L. Reply to Are we certain that chlorhexidine gluconate bathing is not beneficial in deducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation? Cancer. 2021;127(15):2813\u20134. https:\/\/doi.org\/10.1002\/cncr.33570.","journal-title":"Cancer"},{"issue":"1","key":"1192_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/cncr.33271","volume":"127","author":"DM Zerr","year":"2020","unstructured":"Zerr DM, Milstone AM, Dvorak CC, et al. Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children\u2019s Oncology Group. Cancer. 2020;127(1):56\u201366. https:\/\/doi.org\/10.1002\/cncr.33271.","journal-title":"Cancer"},{"key":"1192_CR56","doi-asserted-by":"publisher","first-page":"CD008238","DOI":"10.1002\/14651858.CD008238.pub3","volume":"6","author":"R Gurion","year":"2012","unstructured":"Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;6:CD008238. https:\/\/doi.org\/10.1002\/14651858.CD008238.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"1192_CR57","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/blood-2013-01-476614","volume":"121","author":"L Sung","year":"2013","unstructured":"Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children\u2019s Oncology Group. Blood. 2013;121(18):3573\u20137. https:\/\/doi.org\/10.1182\/blood-2013-01-476614.","journal-title":"Blood"},{"issue":"3","key":"1192_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2006-07-035915","volume":"109","author":"T Lehrnbecher","year":"2007","unstructured":"Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109(3):936\u201343. https:\/\/doi.org\/10.1182\/blood-2006-07-035915.","journal-title":"Blood"},{"issue":"15","key":"1192_CR59","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2009.25.9010","volume":"28","author":"S Ehlers","year":"2010","unstructured":"Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.25.9010.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1192_CR60","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00520-005-0910-8","volume":"14","author":"L Grigull","year":"2006","unstructured":"Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14(7):783\u20136. https:\/\/doi.org\/10.1007\/s00520-005-0910-8.","journal-title":"Support Care Cancer"},{"key":"1192_CR61","doi-asserted-by":"publisher","first-page":"105868","DOI":"10.1016\/j.intimp.2019.105868","volume":"76","author":"A Balch","year":"2019","unstructured":"Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina EY. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol. 2019;76:105868. https:\/\/doi.org\/10.1016\/j.intimp.2019.105868.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1192_CR62","doi-asserted-by":"publisher","first-page":"e28260","DOI":"10.1002\/pbc.28260","volume":"67","author":"HJ Edington","year":"2020","unstructured":"Edington HJ, Sutton KS, Bennett C, Chandrakasan S, Sterner-Allison J, Castellino SM. Dealing with a critical national shortage-Approaches to triaging immune globulin supply in pediatric hematology and oncology. Pediatr Blood Cancer. 2020;67(7):e28260. https:\/\/doi.org\/10.1002\/pbc.28260.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1192_CR63","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428190902856824","volume":"50","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764\u201372. https:\/\/doi.org\/10.1080\/10428190902856824.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1192_CR64","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pbc.23258","volume":"58","author":"CM van Tilburg","year":"2012","unstructured":"van Tilburg CM, Bierings MB, Berbers GA, et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood Cancer. 2012;58(5):701\u20137. https:\/\/doi.org\/10.1002\/pbc.23258.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1192_CR65","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MPH.0000000000001415","volume":"41","author":"EA Holmes","year":"2019","unstructured":"Holmes EA, Friedman DL, Connelly JA, Dulek DE, Zhao Z, Esbenshade AJ. Impact of IgG Monitoring and IVIG Supplementation on the Frequency of Febrile Illnesses in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Maintenance Chemotherapy. J Pediatr Hematol Oncol. 2019;41(6):423\u20138. https:\/\/doi.org\/10.1097\/MPH.0000000000001415.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1192_CR66","first-page":"e2960","volume":"68","author":"HJDN Edington","year":"2021","unstructured":"Edington HJDN, Miller T, et al. Predictors and Outcomes of Immunoglobulin Supplementation in B-cell Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2021;68:e2960.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"1192_CR67","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3109\/10428194.2015.1088652","volume":"57","author":"TP Miller","year":"2016","unstructured":"Miller TP, Getz KD, Kavcic M, et al. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Leuk Lymphoma. 2016;57(7):1567\u201374. https:\/\/doi.org\/10.3109\/10428194.2015.1088652.","journal-title":"Leuk Lymphoma"},{"key":"1192_CR68","doi-asserted-by":"publisher","unstructured":"Getz KD LY, Szymczak JE, Aftandilian C, Arnold SD, O Bona K, Caywood , E CA, Gramatges MM, Henry M, Lotterman C, Maloney K, Mian A, Mody R, Raetz EA, Rubnitz J, Verma A, Winick N, Wilkes JJ, Yu JC, Fisher BT, Aplenc R. Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood. 2019;2019(134)(1).\u00a0https:\/\/doi.org\/10.1182\/blood-2019-131761.","DOI":"10.1182\/blood-2019-131761"},{"issue":"9","key":"1192_CR69","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):833\u201342. https:\/\/doi.org\/10.1001\/jama.2021.0669.","journal-title":"JAMA"},{"issue":"9","key":"1192_CR70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843\u201354. https:\/\/doi.org\/10.1001\/jama.2021.0987.","journal-title":"JAMA"},{"issue":"1","key":"1192_CR71","doi-asserted-by":"publisher","first-page":"e28718","DOI":"10.1002\/pbc.28718","volume":"68","author":"CF Contreras","year":"2021","unstructured":"Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(1):e28718. https:\/\/doi.org\/10.1002\/pbc.28718.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1192_CR72","doi-asserted-by":"publisher","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infect Dis. 2020;7(5):ofaa121. https:\/\/doi.org\/10.1093\/ofid\/ofaa121.","journal-title":"Open Forum Infect Dis"},{"key":"1192_CR73","doi-asserted-by":"crossref","unstructured":"Moskop AVM, Prabhu S, Phillips CL, Stefanski HE, Talano JA, Baggott C, Pacenta HL, Rossoff J, Margossian S, Myers D, Brown PA, Hermiston M, Krukski MC, Wilcox R, Fabrizio VA, Goksenin Y, Karras N, Qayed M, Satwani P, Keating AK, Rabik CA, Chinnabhandar V, Curran KJ, Mackall C, Laetsch TW, Schultz L. Immune Reconstitution and Infections in the Real-World Use of Tisagenlecleucel in Pediatric and Young Adult ALL. Transplant Cell Ther Meet. 2021.\u00a0https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper146393.html.","DOI":"10.1016\/S2666-6367(21)00431-0"},{"issue":"1","key":"1192_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","volume":"123","author":"TD Buitenkamp","year":"2014","unstructured":"Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70\u20137. https:\/\/doi.org\/10.1182\/blood-2013-06-509463.","journal-title":"Blood"},{"issue":"4","key":"1192_CR75","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bjh.14085","volume":"174","author":"EG Salazar","year":"2016","unstructured":"Salazar EG, Li Y, Fisher BT, et al. Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. Br J Haematol. 2016;174(4):591\u20139. https:\/\/doi.org\/10.1111\/bjh.14085.","journal-title":"Br J Haematol"},{"issue":"5","key":"1192_CR76","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jpeds.2009.12.006","volume":"156","author":"BL Bloemers","year":"2010","unstructured":"Bloemers BL, van Bleek GM, Kimpen JL, Bont L. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr. 2010;156(5):804\u20139, 809 e1-809 e5. https:\/\/doi.org\/10.1016\/j.jpeds.2009.12.006.","journal-title":"J Pediatr."},{"issue":"2","key":"1192_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2249.2009.03890.x","volume":"156","author":"MA Kusters","year":"2009","unstructured":"Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009;156(2):189\u201393. https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03890.x.","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"1192_CR78","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood.V124.21.553.553","volume":"124","author":"EKLY Goodman","year":"2014","unstructured":"Goodman EKLY, Seif AE, et al. Treatment toxicity and supportive care utilization in children with Down Syndrome and acute lymphoid leukemia at free-standing pediatric hospitals in the United States. Blood. 2014;124(21):553.","journal-title":"Blood"},{"issue":"4","key":"1192_CR79","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/pbc.23371","volume":"58","author":"KR Rabin","year":"2012","unstructured":"Rabin KR, Smith J, Kozinetz CA. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(4):633\u20135. https:\/\/doi.org\/10.1002\/pbc.23371.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"1192_CR80","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/pbc.26127","volume":"63","author":"F Ceppi","year":"2016","unstructured":"Ceppi F, Stephens D, den Hollander BS, et al. Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(11):1949\u201353. https:\/\/doi.org\/10.1002\/pbc.26127.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1192_CR81","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/pbc.25917","volume":"63","author":"A Hassler","year":"2016","unstructured":"Hassler A, Bochennek K, Gilfert J, et al. Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. Pediatr Blood Cancer. 2016;63(6):1070\u20134. https:\/\/doi.org\/10.1002\/pbc.25917.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"1192_CR82","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/cid\/cis774","volume":"55","author":"D Dix","year":"2012","unstructured":"Dix D, Cellot S, Price V, et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Clin Infect Dis. 2012;55(12):1608\u201314. https:\/\/doi.org\/10.1093\/cid\/cis774.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1192_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-9378-8-47","volume":"8","author":"TH Tran","year":"2013","unstructured":"Tran TH, Mitchell D, Dix D, et al. Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group. Infect Agent Cancer. 2013;8(1):47. https:\/\/doi.org\/10.1186\/1750-9378-8-47.","journal-title":"Infect Agent Cancer"},{"issue":"21","key":"1192_CR84","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/blood.V118.21.1510.1510","volume":"118","author":"ECSW Larsen","year":"2011","unstructured":"Larsen ECSW, Nachman J, et al. Treatment toxicity in adolescents and young adults (AYA) patients compared with younger patients treatment for high risk B-precursor acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group Study AALL0232. Blood. 2011;118(21):1510.","journal-title":"Blood"},{"issue":"5","key":"1192_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12185-018-2503-6","volume":"108","author":"H Sano","year":"2018","unstructured":"Sano H, Kobayashi R, Suzuki D, et al. Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent\/young adult (AYA) and child patients. Int J Hematol. 2018;108(5):543\u20139. https:\/\/doi.org\/10.1007\/s12185-018-2503-6.","journal-title":"Int J Hematol"},{"issue":"12","key":"1192_CR86","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/cncr.32063","volume":"125","author":"C Anderson","year":"2019","unstructured":"Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB. Noncancer mortality among adolescents and young adults with cancer. Cancer. 2019;125(12):2107\u201314. https:\/\/doi.org\/10.1002\/cncr.32063.","journal-title":"Cancer"},{"issue":"1","key":"1192_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14737140.2018.1413939","volume":"18","author":"DJ Harrison","year":"2018","unstructured":"Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39\u201350. https:\/\/doi.org\/10.1080\/14737140.2018.1413939.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1192_CR88","doi-asserted-by":"publisher","unstructured":"Raygor KP, Oh T, Hwang JY, et al. Ventriculoperitoneal shunt infection rates using a standard surgical technique, including topical and intraventricular vancomycin: the Children\u2019s Hospital Oakland experience. J Neurosurg Pediatr. 2020:1\u20139. https:\/\/doi.org\/10.3171\/2020.4.PEDS209.","DOI":"10.3171\/2020.4.PEDS209"},{"issue":"7","key":"1192_CR89","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1302\/2058-5241.4.180081","volume":"4","author":"MA Smolle","year":"2019","unstructured":"Smolle MA, Andreou D, Tunn PU, Leithner A. Advances in tumour endoprostheses: a systematic review. EFORT Open Rev. 2019;4(7):445\u201359. https:\/\/doi.org\/10.1302\/2058-5241.4.180081.","journal-title":"EFORT Open Rev"},{"issue":"2","key":"1192_CR90","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000000938","volume":"262","author":"A Khoshbin","year":"2015","unstructured":"Khoshbin A, So JP, Aleem IS, et al. Antibiotic Prophylaxis to Prevent Surgical Site Infections in Children: A Prospective Cohort Study. Ann Surg. 2015;262(2):397\u2013402. https:\/\/doi.org\/10.1097\/SLA.0000000000000938.","journal-title":"Ann Surg"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01192-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01192-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01192-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:38:11Z","timestamp":1744198691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01192-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01192-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"27 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}